To the extent possible under law, AOP-Wiki has waived all copyright and related or neighboring rights to KE:376
Key Event Title
Increased, Induced Mutations in Critical Genes
|Level of Biological Organization|
Key Event Components
|mutation||cellular tumor antigen p53||increased|
Key Event Overview
AOPs Including This Key Event
Key Event Description
Following the formation of DNA adducts, which are either mis-repaired or not repaired, the sequence of base pairs in the DNA is changed due to insertion of an incorrect base opposite the DNA adduct during DNA replication, so that a G is permanently replaced by a T. This type of mutation is observed in the mutants seen in surrogate gene mutation assays using AFB1 exposureA high frequency of codon 249 p53 mutations occurs in human tumors in high AFB1 exposure regions.Hence, codon 249 of the p53 gene contains a base pair susceptible to insufficient or misrepair of DNA adducts.
Puisieux et al. (1991) provide evidence that the AFB1 epoxide adduct binds preferentially to codon 249 of the p53 gene. Using a plasmid with containing full-length human p53 DNA, adduct formation was observed in exons 5, 6, 7 and 8 (a total of 1086 bases) and 20% of the bases were targeted by AFB1 with a preference for guanine residues. Binding of AFB1 to p53 sequences was restricted to fewer residues and was more specific for guanine than was the binding of B[a]P (Puisieux et al.,1991). Binding of AFB1 in the region around codon 249 of p53 AFB1 was reported to be “stronger” than that of B[a]P. The last nucleotide of codon 249 is a guanine and was targeted by AFB1 but not by B[a]P. This guanine residue is the mutational hotspot in human liver cancers from patients in high AFB1 exposure regions.
While mutations at codon 249 of the p53 gene have been observed in association with HCC in humans, the question remains whether this mutation occurs as a direct result of adduct formation at this site or by some different mechanism..In human HepG2 hepatocytes exposed to microsomally activated AFB1, a dose-dependent increase in G:C to T:A transversions were observed at 10 additional locations using ligation-mediated PCR, and at 4 additional locations using terminal-transferred dependent PCR.(Denissenko et al.,1998). These authors suggest that codon 249 may not present a key adduct site. However, other more recently published data identified codon 249 of the P53 gene as an unusually mutagenic adduct conformation based on the local DNA sequence and concluded that a higher mutation rate may occur there rather than at other locations because of increased DNA polymerase bypass (Pussieux et al., 1991; Lin et al., 2014a,b).
Induced Mutation in Critical Genes
The AFB1-induced pro-mutagenic DNA adduct is either not repaired or is mis-repaired resulting in a mutation in one or more critical genes. In bacteria and mammalian cells (both in vitro and in vivo) the primary mutation associated with AFB1 is a guanine to thymine transversion (Foster et al., 1983; Dycaico et al., 1996). A G:T transversion is expected for the pro-mutagenic DNA adduct AFB1-FAPy.
A specific critical mutation in codon 249 of the p53 gene has been identified in human hepatocellular carcinoma (HCC) (See section below on essentiality).
Level of Biological Organization : Cellular
The induction of mutation occurs within the nucleus of cells and involves permanent alterations in the primary DNA sequence that is passed to subsequent cell generations and, thus, is heritable.
Evidence Supporting Essentiality
A specific critical mutation in the p53 gene has been identified in human hepatocellular carcinoma (HCC). Demonstrating that AFB1 can induce this specific p53 gene mutation would be the highest level of evidence that AFB1-induced HCC involves mutation as a KE. Absent such information, the next best level of evidence is the induction of the specific type of mutation (G:C to T:A transversion) in a variety of gene mutation assays measuring a range of target genes.
The codon 249 mutation is present in a significant proportion of human HCCs. In fact codon 249 mutation is detected in up to 50% of liver cancers in Qidong, China (Hsu et al., 1991) and in Mozambique, both areas with high likelihood of AFB1 exposure. The codon 249 G:C to T:A mutation in the third base is seen in up to 75% of HCC in high-incidence areas of China and East Africa (Gouas et al., 2009). In contrast, this specific mutation is very rare in HCC from areas with no or low exposure to AFB1 (Hsu et al. 1991 and Bressac et al. Nature, 350:429-431, 1991). This mutation is also very rare in other types of tumors (Gouas et al., 2009). According to Gouas et al. (2009), populations with AFB1 exposure are likely to be exposed to hepatitis B virus (HBV) as well and the effects of each are difficult to separate.This mutation is very rare in HCC from non/low -aflatoxin areas (Hsu et al. 1991 and Bressac et al., 1991) and also very rare in other types of tumors.
Some indirect evidence of the essentiality of mutation in tumor development is provided by the clear species difference between adult mice and adult rats both in the induction of surrogate gene mutations and in the induction of tumors. Adult mice exposed to AFB1 do not get tumors and there is no increase in mutant frequency (MF) for Big Blue mice exposed as adults. That is, Lac I mutants from the AFB1- exposed adult mice showed a spontaneous mutational spectrum. Rats, however, showed a large increase in MF and, more specifically a large increase in G:C to T:A transversions (Dycaico et al., 1996). In addition, for mice there is an difference between neonata and adult mice. Neonatal mice treated with AFB1 (6 mg/kg—a dose that does result in tumors) showed an increase in cII mutation with G:C to T:A transversion as the major mutation. Adult mice treated at 6 and 60 mg/kg (doses that do not produce tumors) did not have a significant increase in cII mutation (but did give a different mutational spectrum than controls) (Chen et al. 2010).
How It Is Measured or Detected
Historically the detection of critical cancer gene specific mutations has not been technically feasible. A newly developed method, allele specific competitive blocker-polymerase chain reaction (ACB-PCR) has proven useful in providing such information, and data on specific chemical-induced mutations are available for a very small number of chemicals (Parsons et al., 2010). Unfortunately, there are no data for AFB1.
There are, however, a number of gene mutation assays that have been widely used for determining the general ability of chemicals, including AFB1 to induce mutations.These assays use selection methods that allow only mutant cells to survive and grow. The AS52 in vitro gene mutation assay using the gpt gene, and 6-thioguanine selection has been used to demonstrate that AFB1 exposure increases the MF at the gpt gene. In vivo transgenic assays use molecular methods to recover the transgene from isolated DNA and to evaluate the MF in the transgene. Molecular methods can detect the presence (above a certain sensitivity level) of mutant cells. DNA from tumors can be sequenced to determine the presence of mutations in specific genes. DNA sequencing has been used on human tumors to detect the presence of the Codon 249 p53 mutation.
Domain of Applicability
There are data across phyla demonstrating the induction of mutations, specifically the induction to G:C to T:A transversions following AFB1 exposure.
The induction of G:C to T:A transversions following AFB1 exposure is seen in a wide variety of species from bacteria to mammals. Assays that measure mutation in surrogate genes (that is, genes unrelated to the critical cancer genes) can be used to evaluate the full spectrum of mutational events that can be induced by a chemical. One such system is the AS52 assay, an in vitro mammalian transgenic mutation assay that measures mutation in the gpt gene. After exposure to AFB1 in culture the predominant mutation is G:C to T:A transversion, although a number of other types of mutations were also seen (Wattanawaraporn et al., 2012). There is a species difference between adult mice and rats. No increase in MF is seen in the in vivo Big Blue™ mutation assay for mice exposed to AFB1. That is, Lac I mutations from the mice showed a spontaneous mutational spectrum. By contrast rats showed a large increase in MF with a large increase in G:C to T:A transversions (Dycaico et al., 1996). However, neonatal mice treated with AFB1 (6 mg/kg—a dose that induces tumors in neonates) do show an increase in cII mutation with G:C to T:A transversion as the major mutation. Adult mice treated at 6 and 60 mg/kg (doses that do not induce tumors) did not show a significant increase in cII mutations but did produce a different mutational spectrum than controls (Chen et al., 2010.)
Bressac, B., Kew, M., Wands, J., & Ozturk, M. (1991). Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern africa. Nature, 350(6317), 429-31. doi:10.1038/350429a
Chen, T., Heflich, R. H., Moore, M. M., & Mei, N. (2010). Differential mutagenicity of aflatoxin B1 in the liver of neonatal and adult mice. Environ Mol Mutagen, 51(2), 156-63. doi:10.1002/em.2051
Denissenko MF, Koudriakova TB, Smith L, O'Connor TR, Riggs AD, and Pfeifer GP). The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. (Oncogene. 1998, Dec 10;17(23):3007-14.
Dycaico, M. J., Stuart, G. R., Tobal, G. M., de Boer, J. G., Glickman, B. W., & Provost, G. S. (1996). Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/laci transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis, 17(11), 2347-56
Foster, P. L., Eisenstadt, E., & Miller, J. H. (1983). Base substitution mutations induced by metabolically activated aflatoxin B1. Proceedings of the National Academy of Sciences of the United States of America, 80(9), 2695-8.
Gouas, D., Shi, H., & Hainaut, P. (2009). The aflatoxin-induced TP53 mutation at codon 249 (R249S): Biomarker of exposure, early detection and target for therapy. Cancer Lett, 286(1), 29-37. doi:10.1016/j.canlet.2009.02.057
Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J. A., Wang, N. J., & Harris, C. C. (1991). Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 350(6317), 427-8. doi:10.1038/350427a
Lin YC, Li L, Makarova AV, Burgers PM, Stone MP, Lloyd RS. (2014a). Error-prone replication bypass of the primary aflatoxin B1 DNA adduct, AFB1-N7-Gua. J Biol Chem. 289:18497-18506.
Lin YC, Li L, Makarova AV, Burgers PM, Stone MP, Lloyd RS. (2014b). Molecular basis of aflatoxin-induced mutagenesis-role of the aflatoxin B1-formamidopyrimidine adduct. Carcinogenesis 35(7):1461-1468
Parsons BL, Myers MB, Meng F, Wang Y, McKinzie PB. 2010. Oncomutations as biomarkers of cancer risk. Environ Mol Mutagen. 51(8-9):836-850.
Puisieux, A., Lim, S., Groopman, J., & Ozturk, M. (1991). Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res, 51(22), 6185-9.
Wattanawaraporn, R., Kim, M. Y., Adams, J., Trudel, L. J., Woo, L. L., Croy, R. G., . . . Wogan, G. N. (2012). AFB(1) -induced mutagenesis of the gpt gene in AS52 cells. Environ Mol Mutagen, 53(7), 567-73. doi:10.1002/em.2171